Advertisment

The HeartMate 3: A Lifesaving Device under Scrutiny

author-image
Zara Nwosu
New Update
NULL

The HeartMate 3: A Lifesaving Device under Scrutiny

Advertisment

HeartMate 3: A Lifesaving Device with Alarming Reports

Advertisment

The HeartMate 3, an FDA-approved mechanical heart pump produced by Thoratec Corp., has emerged as a beacon of hope for patients too sick or too old for heart transplants. However, recent reports have raised significant safety concerns about the device. Over 4,500 device-related incidents have been reported since August 2017, with several cases leading to serious injuries and even fatalities. Lawsuits have been filed against Thoratec Corp., alleging device failures that resulted in severe brain injury, multiorgan failure, and death in patients.

Manufacturer Denies Liability Amidst Growing Concerns

Despite the alarming number of reports, the manufacturer maintains that the HeartMate 3 is safe in nearly 90% of cases. They even confirmed a defect in the device's locking mechanism in two cases mentioned in lawsuits but denied any liability. This stance has been met with significant skepticism, particularly as former FDA officials and experts call for further investigation. These experts view the high number of death reports as a safety signal that cannot be ignored.

Advertisment

Limitations of the FDA's Database and Lack of Transparency

Adding to the concern is the limitations of the FDA's Medical Device Reporting (MDR) system, known as MAUDE. This database, designed to collect and analyze adverse events, has been criticized for its lack of transparency and detailed context. These limitations make it difficult for patients and doctors to understand the safety history of the HeartMate 3. Reports lodged in MAUDE have cited infusion or flow problems, bleeding, infection, and respiratory failure among the adverse events experienced by HeartMate 3 patients.

The Challenge of Postmarket Surveillance

Advertisment

The issues surrounding the HeartMate 3 highlight the broader challenges in the postmarket surveillance of medical devices. The FDA has struggled to keep the MAUDE database up to date, with millions of follow-up reports pending for the HeartMate 3 and other devices. In addition, device makers often take longer than the required 30 days to investigate the root cause of an incident, often concluding that user error was to blame. This has resulted in a lack of detailed information available to the public, leaving patients and healthcare providers in the dark about the potential risks associated with the device.

Seeking More Transparency and Safety Measures

The FDA has a responsibility to monitor and maintain public reporting of adverse events. In the case of the HeartMate 3, this includes more than 8,000 complaints received by Thoratec in the 12 months leading up to an FDA inspection in October 2020. The FDA also relies on a range of sources, including published literature, patients, patient advocacy groups, professional societies, and individual healthcare providers, to determine whether further action is needed. As the situation with the HeartMate 3 unfolds, there is a clear call for more transparency, thorough investigation, and robust safety measures to protect patient health.

Advertisment
Chat with Dr. Medriva !